kl-a167
Showing 1 - 4 of 4
Triple-negative Breast Cancer Trial in Changsha, Nanjing (SKB264, KL-A167)
Not yet recruiting
- Triple-negative Breast Cancer
- SKB264
- KL-A167
-
Changsha, Hunan, China
- +1 more
Jun 30, 2022
Nasopharyngeal Carcinoma, Recurrent or Metastatic Trial in Beijing (KL-A167, Gemcitabine, Cisplatin)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Recurrent or Metastatic
- KL-A167
- +3 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Mar 23, 2022
NSCLC Trial in Guangzhou (SKB264, KL-A167, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- SKB264
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Apr 24, 2022
Classical Hodgkin Lymphoma Trial (KL-A167)
Unknown status
- Classical Hodgkin Lymphoma
- KL-A167
- (no location specified)
Jun 26, 2018